- |||||||||| Trial termination, Trial primary completion date: Performance of Continuous Glucose Monitoring Systems at Altitude (clinicaltrials.gov) - Oct 28, 2015
P=N/A, N=10, Terminated, Trial primary completion date: Dec 2014 --> Dec 2016 Suspended --> Terminated | Trial primary completion date: Jul 2012 --> Jul 2017; Suspended awaiting Ministry of Defence ethics approval.
- |||||||||| BIIB023 / Biogen
Trial termination, Trial primary completion date: ATLAS: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (clinicaltrials.gov) - Oct 28, 2015 P2, N=188, Terminated, Trial primary completion date: Mar 2016 --> Dec 2015 Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2015; Results from a pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.
- |||||||||| BIIB023 / Biogen
Enrollment change, Trial termination, Trial primary completion date: BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis (clinicaltrials.gov) - Oct 28, 2015 P2, N=87, Terminated, Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2015; Results from a pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study. N=155 --> 87 | Enrolling by invitation --> Terminated | Trial primary completion date: Feb 2019 --> Dec 2015; Results from pre-specified criteria in study NCT01499355 did not demonstrate sufficient efficacy to warrant continuation of the study
- |||||||||| Enrollment closed: Mussels, Inflammation and Rheumatoid Arthritis (MIRA) (clinicaltrials.gov) - Oct 28, 2015
P=N/A, N=40, Active, not recruiting, N=155 --> 87 | Enrolling by invitation --> Terminated | Trial primary completion date: Feb 2019 --> Dec 2015; Results from pre-specified criteria in study NCT01499355 did not demonstrate sufficient efficacy to warrant continuation of the study Recruiting --> Active, not recruiting
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date: MENTOR: MEmbranous Nephropathy Trial Of Rituximab (clinicaltrials.gov) - Oct 27, 2015 P2/3, N=126, Active, not recruiting, Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Oct 2016
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: China Betaferon Adherence, Coping and Nurse Support Study (clinicaltrials.gov) - Oct 27, 2015 P=N/A, N=110, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Oct 2016 Active, not recruiting --> Completed
- |||||||||| Tavalisse (fostamatinib) / Rigel
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy (clinicaltrials.gov) - Oct 23, 2015 P2, N=0, Withdrawn, Enrolling by invitation --> Completed N=25 --> 0 | Initiation date: Jun 2015 --> Sep 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2017 --> Sep 2015
- |||||||||| methylphenidate tablet / Generic mfg.
Trial primary completion date: Methylphenidate to Improve Balance and Walking in MS (clinicaltrials.gov) - Oct 23, 2015 P2/3, N=24, Recruiting, Trial primary completion date: Sep 2015 --> Apr 2016 Trial primary completion date: Jul 2015 --> Jan 2016
|